Rogers J, Bueno J, Shapiro R, Scantlebury V, Mazariegos G, Fung J, Reyes J
Section of Transplant Surgery, Department of Surgery, Medical University of South Carolina, Charlston, SC, USA.
Transplantation. 2001 Nov 27;72(10):1666-70. doi: 10.1097/00007890-200111270-00016.
The indications for simultaneous and sequential pediatric liver (LTx) and kidney (KTx) transplantation have not been well defined. We herein report the results of our experience with these procedures in children with end-stage liver disease and/or subsequent end-stage renal disease.
Between 1984 and 1995, 12 LTx recipients received 15 kidney allografts. Eight simultaneous and seven sequential LTx/KTx were performed. There were six males and six females, with a mean age of 10.9 years (1.5-23.7). One of the eight simultaneous LTx/KTx was part of a multivisceral allograft. Five KTx were performed at varied intervals after successful LTx, one KTx was performed after a previous simultaneous LTx/KTx, and one KTx was performed after previous sequential LTx/KTx. Immunosuppression was with tacrolimus or cyclosporine and steroids. Indications for LTx were oxalosis (four), congenital hepatic fibrosis (two), cystinosis (one), polycystic liver disease (one), A-1-A deficiency (one), Total Parenteral Nutrition (TPN)-related (one), cryptogenic cirrhosis (one), and hepatoblastoma (one). Indications for KTx were oxalosis (four), drug-induced (four), polycystic kidney disease (three), cystinosis (one), and glomerulonephritis (1).
With a mean follow-up of 58 months (0.9-130), the overall patient survival rate was 58% (7/12). One-year and 5-year actuarial patient survival rates were 66% and 58%, respectively. Patient survival rates at 1 year after KTx according to United Network of Organ Sharing (liver) status were 100% for status 3, 50% for status 2, and 0% for status 1. The overall renal allograft survival rate was 47%. Actuarial renal allograft survival rates were 53% at 1 and 5 years. The overall hepatic allograft survival rate was equivalent to the overall patient survival rate (58%). Six of seven surviving patients have normal renal allograft function, and one patient has moderate chronic allograft nephropathy. All surviving patients have normal hepatic allograft function. Six (86%) of seven sequentially transplanted kidneys developed acute cellular rejection compared with only two (25%) of eight simultaneously transplanted kidneys (P<0.04).
Simultaneously transplanted kidneys were less likely to develop rejection than sequentially transplanted kidneys in this series. This did not have any bearing on patient or graft survival rates. Mortality correlated directly with the severity of United Network of Organ Sharing status at the time of kidney transplantation. Candidates for simultaneous or sequential LTx/KTx should be prioritized based on medical stability to optimize distribution of scarce renal allografts.
儿童同期和序贯肝移植(LTx)及肾移植(KTx)的适应证尚未明确界定。我们在此报告我们对患有终末期肝病和/或随后的终末期肾病儿童进行这些手术的经验结果。
1984年至1995年间,12例肝移植受者接受了15次肾移植。进行了8例同期和7例序贯肝/肾移植。有6名男性和6名女性,平均年龄为10.9岁(1.5 - 23.7岁)。8例同期肝/肾移植中有1例是多脏器移植的一部分。5例肾移植在肝移植成功后的不同时间间隔进行,1例肾移植在先前的同期肝/肾移植后进行,1例肾移植在先前的序贯肝/肾移植后进行。免疫抑制采用他克莫司或环孢素及类固醇。肝移植的适应证为草酸沉积症(4例)、先天性肝纤维化(2例)、胱氨酸病(1例)、多囊肝病(1例)、α1 - 抗胰蛋白酶缺乏症(1例)、全胃肠外营养(TPN)相关(1例)、隐源性肝硬化(1例)和肝母细胞瘤(1例)。肾移植的适应证为草酸沉积症(4例)、药物性(4例)、多囊肾病(3例)、胱氨酸病(1例)和肾小球肾炎(1例)。
平均随访58个月(0.9 - 130个月),总体患者生存率为58%(7/12)。1年和5年的精算患者生存率分别为66%和58%。根据器官共享联合网络(肝脏)状态,肾移植后1年的患者生存率,状态3为100%,状态2为50%,状态1为0%。总体肾移植生存率为47%。1年和5年的精算肾移植生存率分别为53%。总体肝移植生存率与总体患者生存率相当(58%)。7例存活患者中有6例肾移植功能正常,1例患者有中度慢性移植肾肾病。所有存活患者肝移植功能正常。7例序贯移植肾中有6例(86%)发生急性细胞排斥反应,而8例同期移植肾中只有2例(25%)发生(P<0.04)。
在本系列中,同期移植的肾发生排斥反应的可能性低于序贯移植的肾。这对患者或移植物生存率没有任何影响。死亡率与肾移植时器官共享联合网络状态的严重程度直接相关。同期或序贯肝/肾移植的候选者应根据医疗稳定性进行优先排序,以优化稀缺肾移植的分配。